Homrich & Berg’s Acorda Therapeutics ACOR Stock Holding History

Homrich & Berg’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-125	Closed	-$8K	–	413
2020 Q3	$8K	Buy	+125	New	+$9.43K	﹤0.01%	340

Other funds holding ACOR

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Homrich & Berg's ACOR Position: Q4 2020 in Review

Homrich & Berg sold out of Acorda Therapeutics (ACOR) in Q4 2020, closing a stake of 125 shares — an estimated $8K sold.

Homrich & Berg first reported a position in ACOR in Q3 2020 and held it in 1 quarter. The position peaked at $8K in Q3 2020. 47 funds tracked by Wall St. Rank hold ACOR as of Q4 2020.

Homrich & Berg reported no remaining Acorda Therapeutics position as of Q4 2020 after selling out during the quarter.
Homrich & Berg sold 125 Acorda Therapeutics shares in Q4 2020, an estimated $8K.
Homrich & Berg first reported a position in Acorda Therapeutics in Q3 2020 and held it in 1 quarter.
Homrich & Berg's Acorda Therapeutics position peaked at $8K in Q3 2020.
47 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2020.

Based on Homrich & Berg's 13F filing for Q4 2020, filed 16 Feb 2021.